LUND, SWEDEN--(Marketwire - March 15, 2011) -
Dr. Helén Tuvesson takes up the post as Chief Scientific Officer
within Active
Biotech from April 1, 2011. Helén Tuvesson will be reporting
to Tomas
Leanderson, President & CEO.
Dr. Tuvesson has worked in the pharmaceutical industry for more than 20 years and has extensive experience in drug development, from the early preclinical stage up to late clinical development. Helén has been on different positions within Active Biotech since 1998, most recently as Head of the department of Preclinical Development. She has been a member of the R&D management for three years, and the recent year also in the senior management team at Active Biotech.
The appointment will strengthen Active Biotech's R&D capabilities going forward after the recent positive results obtained in the laquinimod and TASQ clinical studies.
Lund, March 15, 2011 Active Biotech AB (publ)
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
with
focus on autoimmune/inflammatory diseases and cancer. Projects in or
entering
pivotal phase are laquinimod, an orally administered small molecule with
unique
immunomodulatory properties for the treatment of multiple sclerosis,
TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy,
primarily of
renal cell cancer. In addition, laquinimod is in Phase II
development for
Crohn's and Lupus. Further projects in clinical development comprise
the two
orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as
well as
RhuDex™ for RA. Please visit www.activebiotech.com for more
information.
Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 3:00 pm CET on March 15, 2011.
Helén Tuvesson appointed as new Chief Scientific Officer at Active Biotech: http://hugin.info/1002/R/1497045/432783.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1497045]
For further information, please contact:
Tomas Leanderson
Tel: +46 (0)46 19 20 95
E-mail: Email Contact
